By Colin Kellaher
Immunovant unveiled a series of executive changes that more closely aligns the clinical-stage immunology company with majority shareholder Roivant Sciences.
Immunovant on Monday said Pete Salzmann has retired as chief executive and a director of the New York company, and that Eric Venker, a board member who also serves as Roivant's president, has stepped in as CEO.
The company said Salzmann, who joined as CEO in 2019, will be eligible for severance benefits as part of a separation agreement.
Immunovant also said Renee Barnett has stepped down as chief financial officer and has been succeeded by Tiago Girao, who has served as finance chief for multiple Roivant units since 2019.
The company said Barnett, 45 years old, will receive an annual base salary of $481,000 and an annual bonus with a target of 45% of his base pay, adding that it expects to sign a separation agreement with Barnett that includes severance benefits.
Immunovant said the executive changes are part of a broader strategic transition with Roivant that increases the pharmaceutical company's operational involvement and strategic oversight of Immunovant, which was spun out of Roivant in 1999.
Roivant still owns about 57% of Immunovant.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 21, 2025 07:44 ET (11:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。